Cohance Lifesciences Ltd
NSE:COHANCE

Watchlist Manager
Cohance Lifesciences Ltd Logo
Cohance Lifesciences Ltd
NSE:COHANCE
Watchlist
Price: 475.9 INR -3.44% Market Closed
Market Cap: 182.1B INR

Relative Value

The Relative Value of one COHANCE stock under the Base Case scenario is hidden INR. Compared to the current market price of 475.9 INR, Cohance Lifesciences Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COHANCE Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
80
vs Industry
Median 3Y
20.5
Median 5Y
20.5
Industry
2.7
Forward
6.6
vs History
80
vs Industry
Median 3Y
121.4
Median 5Y
121.4
Industry
21.6
Forward
39.4
vs History
80
vs Industry
Median 3Y
107.8
Median 5Y
107.8
Industry
16.9
vs History
80
vs Industry
Median 3Y
224.9
Median 5Y
224.9
Industry
22.9
vs History
80
vs Industry
Median 3Y
18.3
Median 5Y
18.3
Industry
2.3
vs History
80
vs Industry
Median 3Y
20.4
Median 5Y
20.4
Industry
3
Forward
6.6
vs History
80
vs Industry
Median 3Y
27.5
Median 5Y
27.5
Industry
5.6
vs History
80
vs Industry
Median 3Y
82.4
Median 5Y
82.4
Industry
13.4
Forward
24.7
vs History
80
vs Industry
Median 3Y
103.8
Median 5Y
103.8
Industry
16.7
Forward
30.3
vs History
80
vs Industry
Median 3Y
107.4
Median 5Y
107.4
Industry
16.1
vs History
80
vs Industry
Median 3Y
233.7
Median 5Y
233.7
Industry
18.9
vs History
80
vs Industry
Median 3Y
11.6
Median 5Y
11.6
Industry
2

Multiples Across Competitors

COHANCE Competitors Multiples
Cohance Lifesciences Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Cohance Lifesciences Ltd
NSE:COHANCE
182.1B INR 12 71.1 48.2 60.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.6 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
491.8B USD 5.3 19.6 16 20.8
CH
Roche Holding AG
SIX:ROG
271.4B CHF 4.4 28.8 12.2 14.3
UK
AstraZeneca PLC
LSE:AZN
220.4B GBP 5.1 31.4 108.8 159.2
US
Merck & Co Inc
NYSE:MRK
274.9B USD 4.3 14.4 10.2 12.1
CH
Novartis AG
SIX:NOVN
218.8B CHF 4.9 19 12 15.5
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.4 16.3 11.3 13.2
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.9B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Cohance Lifesciences Ltd
NSE:COHANCE
Average P/E: 30
71.1
49%
1.5
US
Eli Lilly and Co
NYSE:LLY
54.6
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28.8
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.4
37%
0.8
US
Merck & Co Inc
NYSE:MRK
14.4
15%
1
CH
Novartis AG
SIX:NOVN
19
17%
1.1
DK
Novo Nordisk A/S
CSE:NOVO B
16.3
3%
5.4
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Cohance Lifesciences Ltd
NSE:COHANCE
Average EV/EBITDA: 404.4
48.2
47%
1
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16
9%
1.8
CH
Roche Holding AG
SIX:ROG
12.2
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
US
Merck & Co Inc
NYSE:MRK
10.2
6%
1.7
CH
Novartis AG
SIX:NOVN
12
6%
2
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
1%
11.3
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Cohance Lifesciences Ltd
NSE:COHANCE
Average EV/EBIT: 1 717.9
60.7
49%
1.2
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14.3
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
US
Merck & Co Inc
NYSE:MRK
12.1
8%
1.5
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5